Physician profile

Joshua M Gitlin

Interventional Pain Medicine · Bloomfield Hills, MI

NPI 1730241555

$8,444.14

in general payments reported to CMS, 2019-2025

46 companies · $1,489 in 2025

The $1,489 reported for 2025 was more than what a typical Interventional Pain Medicine provider received nationally (typical 2025 total: $676).

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$4,816.82

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Nevro Corp. $1,708.65 2019-2024 Senza
Collegium Pharmaceutical, INC. $906.44 2019-2025 Xtampza, Belbuca
Globus Medical, INC. $765.39 2025 Senza, Vyrsa V1
Abbvie INC. $492.60 2022-2025
Abbott Laboratories $427.76 2019-2025 Proclaim, Eterna
Scilex Pharmaceuticals INC. $386.19 2019-2023 Ztlido
Medtronic USA, INC. $380.18 2019-2020
Vertos Medical, INC. $343.41 2021-2024 Mild Device Kit
Boston Scientific Corporation $277.15 2019-2025 Intracept
Nalu Medical, INC. $272.99 2022-2025 Nalu Neurostimulation System
Spr Therapeutics, INC $230.48 2020-2024 Sprint Pns System
Medtronic, INC. $227.08 2021-2025 Inceptiv, Intellis Adaptivestim
Amgen INC. $223.80 2019-2022
Saluda Medical Americas, INC. $213.95 2023-2025 Evoke Scs, Evoke
Allergan, INC. $187.98 2019-2022
Show all 46 companies
CompanyGeneral paymentsYearsTop products
Averitas Pharma INC. $142.43 2023-2025 Qutenza
Sanofi-Aventis U.S. LLC $124.51 2019-2022
Biodelivery Sciences International, INC. $123.51 2019-2021
Novartis Pharmaceuticals Corporation $97.47 2020-2021
Salix Pharmaceuticals, A Division of Bausch Health US, LLC $83.78 2020-2022
Pacira Pharmaceuticals Incorporated $74.44 2023-2025 Exparel, Iovera, Zilretta
Tersera Therapeutics LLC $65.62 2019-2024 Prialt
Redhill Biopharma INC. $63.33 2022
Mdd US Operations, LLC $55.90 2019
Daiichi Sankyo INC. $54.55 2019
Grt US Holding, INC. $52.08 2021-2022
Bioventus LLC $48.59 2019-2022
Pfizer INC. $47.00 2019
Vertex Pharmaceuticals Incorporated $43.94 2025
Pacira Therapeutics, INC. $31.63 2019
Virtus Pharmaceuticals LLC $29.95 2020-2021
Electronic Waveform Lab, INC. $27.86 2019
Teva Pharmaceuticals USA, INC. $23.30 2020
Tonix Medicines, INC. $22.91 2025 Tonmya
Spinal Simplicity, LLC $20.36 2025 Ha Minuteman G3-R
Biogen, INC. $19.60 2021
Biotronik Nro, INC. $19.60 2025
Biotissue Holdings INC. $17.51 2024
Stimwave Technologies Incorporated $17.18 2022
Biohaven Pharmaceutical Holding Company Ltd. $16.80 2022
Ibsa Pharma INC. $14.78 2021
Horizon Therapeutics Plc $14.30 2021
Arbor Pharmaceuticals, INC. $13.91 2021
Takeda Pharmaceuticals U.S.A., INC. $12.56 2019
Fidia Pharma USA INC. $10.88 2019
Brainsway USA INC $9.81 2022

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Joshua M Gitlin

$8,444.14

in general payments reported 2019-2025

Years
2019-2025
Top company
Nevro Corp.
Context
The $1,489 reported for 2025 was more than what a typical Interventional Pain Medicine provider received nationally (typical 2025 total: $676).

https://glasscript.com/doctor/78733/joshua-m-gitlin

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.